ImmunityBio Inc. shares were up 23% to $7.87 after Australia-based EnGeneIC said it will grant ImmunityBio a license for nanocell technology in combination with anti-cancer drugs and Covid-19 vaccines.
ImmunityBio will build manufacturing facilities in the U.S. and South Africa.
On Nov. 18, ImmunityBio said it is expanding its vaccine programs, including accelerating use of "mix-and-match" technologies to develop potential Covid-19 vaccines.
ImmunityBio reported favorable data from a Phase 1 study of a Covid-19 vaccine candidate in April. In November, ImmunityBio and Amyris Inc. announced plans for a joint venture to accelerate the commercialization of a Covid-19 vaccine.
https://www.marketwatch.com/story/immunitybio-up-23-on-license-agreement-with-engeneic-271638304697
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.